Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral therapeutics targeting the replication processes of various viral diseases, including influenza, COVID-19, hepatitis C, and norovirus. The company employs a proprietary structure-based drug discovery strategy that leverages advanced structural biology, enzymology, and medicinal chemistry. This approach allows Cocrystal to create small molecule therapeutics that are not only effective but also safe and convenient for administration. Their technology provides near-atomic resolution insights into inhibitor complexes, facilitating the identification of novel binding sites and enabling rapid structural information processing.

The company's development programs emphasize the creation of broad-spectrum antiviral agents that can effectively combat multiple viral strains, addressing the challenge of viral resistance. By targeting highly conserved replication enzymes across different viruses, Cocrystal aims to develop therapies with a high barrier to resistance, ensuring efficacy even against mutated strains. Their focus on direct-acting antiviral drugs (DAAs) for hepatitis C, particularly ultrashort treatment regimens, exemplifies their commitment to improving patient outcomes through innovative therapeutic strategies. Cocrystal's research is underpinned by the expertise of Dr. Roger Kornberg, a Nobel Prize-winning scientist whose work has significantly advanced the understanding of viral replication mechanisms.

United States

Cocrystal Pharma, Inc. is a clinical stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Infectious Diseases

Liver Diseases

Lung Diseases

Cocrystal Pharma

Hepatitis C

CC-31244 is an investigational, oral, broad-spectrum replication &nbsp;inhibitor called a non-nucleoside inhibitor (NNI). It has been designed &nbsp;and developed using the Company's proprietary structure-based drug &nbsp;discovery technology to have a high barrier to drug resistance and to be &nbsp;a highly potent, selective NNI that is active against all HCV genotypes &nbsp;(1-6) with low level cytotoxicity in multiple cell types.
<a href="https://www.cocrystalpharma.com/news/press-releases/detail/75/cocrystal-pharmapresents-positive-data-from-u-s-phase-2a">Source</a>

CC-31244  (Pan-genotypic NS5B NNI)

Influenza

Oral CC-42344

COVID-19

Norovirus

CDI-988 was specifically designed and developed as a broad-spectrum antiviral inhibitor using Cocrystal’s proprietary structure-based drug discovery platform technology. It targets a highly conserved region in the active site of coronaviruses, noroviruses and other 3CL viral proteases. Cocrystal is approved to conduct a CDI-988 Phase 1 study in Australia by that country’s Human Research Ethics Committee (HREC)

CDI-988

Inhaled CC-42344

CDI-45205 is a coronavirus replication and protease inhibitor

Cocrystal Pharma

Company Details